30 October 2024
ANANDA
DEVELOPMENTS PLC
("Ananda"
or the "Company")
Unaudited Interim Results for
the six months ended 31 July 2024
The Directors present the
consolidated interim results of Ananda Developments Plc, together
with its subsidiaries (the "Group") for the period from
1 February 2024 to 31 July 2024.
UPDATE ON OPERATIONS
Ananda is dedicated to developing
medicines to treat complex, chronic inflammatory pain conditions.
With 28 million people in the UK alone dealing with chronic pain
and the NHS spending over £5 billion annually on musculoskeletal
pain, there is a pressing need for better, more effective
treatments as in many of these conditions, which exhibit complex,
chronic inflammation and pain, there is significant unmet medical
need.
We believe in the transformative
potential of cannabinoids, supported by a growing body of clinical
and real-world evidence. Our commitment is to deliver:
· Robust
clinical trial evidence through partnerships with world-leading
researchers and key opinion leaders
· The
highest quality cannabinoid medicines, manufactured to the
strictest pharmaceutical standards
· Licensed cannabinoid medicines available initially on the NHS
before looking to the global market
Our patent-pending MRX1 CBD
formulation is being used in two fully funded Phase II randomised
controlled trials into:
· chemotherapy induced nerve pain; and
· endometriosis
As announced earlier this month
our patent-pending
MRX2 and MRX2T CBD and CBD + tetrahydrocannabinol (THC)
formulations have been selected as the active pharmaceutical
ingredients in two funded Phase III randomised controlled
trials into:
· refractory (drug-resistant) early onset epilepsies;
and
· refractory genetic generalised epilepsies
In these trials, which are funded by
NIHR and NHS England, researchers will study whether MRX2 &
MRX2T are safe and effective in reducing the number and severity of
seizures experienced by people with epilepsy, as well as their
effects on learning, sleep, behaviour, quality of life, stress, and
anxiety.
The two studies will be the world's
first double blind randomised controlled trials to investigate the
use of CBD and THC together for epilepsy, and the first to evaluate
the medicines in children and adults who have a broad range of
difficult-to-treat epilepsies. Previously, double blind randomised
controlled trials investigated the use of CBD-only in three rare
conditions associated with drug-resistant epilepsy (Dravet
Syndrome, Lennox Gastaut Syndrome, and tuberous sclerosis
complex).
Over 18 months, 500 patients will be
recruited across the UK at multiple NHS sites. The patients will be
randomly assigned either CBD, a combination of CBD and THC, or a
matched placebo supplied by Ananda
Developments plc. The
formulations being used for the trials are Ananda's patent pending
MRX2 (CBD) Oral Solution, MRX2T (CBD + THC) Oral Solution, and a
matched placebo. The scale and design of the Phase III trials will
provide a greater understanding of both the benefits and potential
risks of MRX2 and MRX2T as new treatments.
Also announced after the end of the
period, our patent-pending MRX1 CBD formulation is to undergo
pharmacokinetic assessment in a Phase I study.
Also announced during the period,
positive pre-clinical study results were received for our
patent-pending MRX1 CBD formulation in the potential treatment
of Heart
Fibrosis with Preserved Ejection
Fraction.
We continue to investigate trials in
other conditions including Heart Fibrosis with Preserved Ejection
Fraction, as we aim to build a comprehensive pre-clinical
pipeline.
During the 6 months to 31 July 2024,
the team focused on advancing the two Phase II clinical trials.
This involved work to ensure a robust supply chain for the
manufacture of the investigative medicines, writing the
Investigator Brochure and Investigational Medicinal Product Dossier
for the patent-pending MRX1 CBD formulation, obtaining quotes for
the pharmacokinetic study, liaising with the clinical trial teams
at the University of Edinburgh and preparing submissions to the
ethics committee in advance of dosing. Ethics approval is a key
step towards dosing commencing in trial patients.
We have also been assessing
regulatory, market access and pricing strategies with support of
independent specialist advisors. We are working to ensure the
clinical trials programme is designed in a way that is most likely
to lead to marketing authorisations and healthcare provider uptake,
principally via the NHS in the UK and in other
countries.
During the period we announced the
formation of Ananda's Scientific Advisory Board. Chaired by
Ananda's independent non-executive director Professor Clive Page,
we are fortunate to have the added guidance of Professor Trevor
Jones and Professor Cherry Wainright as we work towards our
objective of delivering licenced CBD drugs to the NHS to treat
complex chronic inflammatory pain conditions. Ananda held its first
Scientific Advisory Board meeting at the Royal College of Surgeons
in Edinburgh during May 2024. It was a very constructive day
where we discussed each trial in detail and the Company's
plans for further trials and received feedback and input from
specialist scientists. Following the end of the period, we welcomed
Professor Marie Fallon, the Lead Investigator on our CIPN trial, to
the Scientific Advisory Board. Professor Fallon is the Lead
Investigator on our CIPN trial and a key opinion leader in the
treatment of cancer pain.
By collaborating with respected
researchers, like Professor Fallon, we believe we are well
positioned to secure NHS availability for our patent-pending CBD
based medicines.
Throughout
the period, we maintained active communication with our
shareholders, providing updates and engaging through our
Hub. This hub facilitates access
to Company news, market data, and allows us to respond directly to
shareholder questions. Please sign up for the Investor Hub
here.
Through our Investor Hub, we
published several blogs/presentations that form part of a series on
clinical and pre-clinical trials and clinical development. So far
we have released:
·
An Introduction to Cannabidiol (CBD)
·
What Happens Before a Clinical Trial Starts?
·
What is the Purpose of a Pharmacokinetic
Study?
·
Why Run a Phase 1 Study in Australia?
·
What Happens During a Pharmacokinetic Study?
·
Therapeutic Potential of CBD
We intend to publish more blogs and
presentations in the coming months. These will cover the work that
goes on before, during and after clinical trials as well as why we
take certain steps in the development pathway. All will be
available on our Hub, so
please sign up!
Also during the period, we announced
the encouraging
results of a pre-clinical study we ran in partnership with Robert
Gordon University. This trial
investigated the use of MRX1, our patent pending CBD-based
formulation, in mice with Heart Fibrosis with preserved Ejection
Fraction ('HFpEF'). In summary:
· Administration of MRX1 has shown significant cardioprotective
effects in a mouse study, demonstrating its potential as a
treatment for patients with heart failure with preserved ejection
fraction (HFpEF).
· The
research involved detailed assessments of cardiac function, plasma
CBD levels, and molecular markers of heart failure, fibrosis, and
inflammation.
· MRX1
exhibited multiple traits which indicate an effectiveness in
mitigating cardiac fibrosis and improving heart health.
· These
data have been included in Ananda's International Patent
Application for MRX1.
· The
data was presented on 25 June 2024 for the first time at the 9th
Federation of European Pharmacological Societies (EPHAR) conference
in Athens.
· The
successful outcomes suggest MRX1 could be a valuable therapeutic
option for HFpEF and other cardiac conditions. Ananda is currently
investigating next steps on how to bring this promising treatment
to clinical use.
Earlier this year Ananda joined the
Cannabinoid Research and Development Group, which is co-Chaired by
Professor Trevor Jones and George Freeman MP. The group is
executing a strategy to establish the UK as a global leader in
R&D in cannabinoid science by building a robust ecosystem -
integrating universities, research institutions, investors,
businesses, and the NHS, to advance the understanding of cannabis
and its derivatives.
On the 15 July 2024, the Company published its annual report and
audited accounts. The report
contains a compelling case study for CBD on pages 7&8, which
makes particularly worthwhile reading.
After the end of the reporting
period we announced the completion
of a capital raising. The
fund raising of £2.2m was cornerstoned by Ananda's Chairman,
Charles Morgan who invested approximately £2 million, continuing to
show his commitment to Ananda's activities and potential. At the
same time both Charles and I capitalised unsecured debt of
approximately £1.9m to cleanse the Company's balance sheet of all
outstanding debt besides the 2023 Convertible Loan Notes. This fund
raising would not have been possible without the added support of
our wider shareholder base, who
participated via a WRAP Retail Offer. I would like to thank everyone who
participated in this offer.
In the period, the Group incurred a
loss of £1,213,270 before tax. This was largely made up of expenses
related to the pursuit of our clinical trials. Net liabilities of
the Group at the interim point were £860,309, mostly made up of
outstanding 2023 issued Convertible Loan Notes which expire in
November 2025.
On behalf of the board,
Melissa Sturgess, Chief Executive
Officer
30 October 2024
Directors Report
The directors present their
consolidated interim financial statements of the Group for the
period from 1 February 2023 to 31 July 2024.
Directors of the company
The directors who have served during
the period and up to the date of approval were as
follows:
Charles Morgan
Melissa Sturgess
John Treacy
Stuart Piccaver
Clive Page
Jeremy Sturgess-Smith
Results
The consolidated statement of
comprehensive income is set out below and shows the loss for
six-month period to 31 July 2024. The directors consider the
loss for the period to be line with expectations. The directors do
not recommend the payment of a dividend.
This report was approved by the
Board and signed on its behalf.
Melissa Sturgess, Chief Executive
Officer
30 October 2024
Consolidated Interim Statement of Comprehensive
Income
|
|
|
|
Group
6 months to 31 July
2024
Unaudited
|
Group
Year ended 31 January
2024
Audited
|
Group
6 months to 31 July
2023
Unaudited
|
|
|
Note
|
|
£
|
£
|
£
|
|
|
|
|
|
|
|
|
Revenue
|
|
|
764
|
|
|
|
Administrative expenses
|
|
|
(756,938)
|
(1,729,317)
|
(844,456)
|
|
|
|
|
|
|
|
|
Impairment
|
|
|
-
|
(3,873,816)
|
|
|
Depreciation
|
|
|
(315,808)
|
(1,190,155)
|
(101,025)
|
|
Interest payable
|
|
|
(144,129)
|
(138,806)
|
(44,412)
|
|
Interest receivable
|
|
|
167
|
27
|
|
|
|
|
|
|
|
|
|
Loss from operations
|
|
|
(1,215,944)
|
(6,932,067)
|
(989,893)
|
|
|
|
|
|
|
|
|
Taxation
|
|
|
2,697
|
781,280
|
-
|
|
|
|
|
|
|
|
|
Other Comprehensive Income
|
1
|
|
|
|
|
|
R&D repayment
|
|
|
-
|
6,624
|
-
|
|
Royalties
|
|
|
(23)
|
-
|
-
|
|
|
|
|
|
|
|
|
Total loss for the period
|
|
|
(1,213,270)
|
(6,144,163)
|
(989,893)
|
|
Earnings per share
|
|
|
|
|
|
|
Basic and diluted earnings per share
(pence)
|
2
|
|
(0.04p)
|
(0.23p)
|
(0.08p)
|
There was no other comprehensive
income in the period.
The notes form part of these
consolidated interim financial statements.
Consolidated Interim Statement of Financial
Position
|
|
|
|
Group
6 months to 31 July
2024
Unaudited
|
Group
Year ended 31 January
2024
Audited
|
Group
6 months to 31 July
2023
Unaudited
|
|
|
|
|
£
|
£
|
£
|
|
Non-Current assets
|
|
|
|
|
|
|
Tangible assets
|
|
|
1,466,641
|
1,566,303
|
1,664,405
|
|
Intangible assets
|
|
|
1,675,182
|
1,874,839
|
5,827,228
|
|
Investments in
subsidiaries
|
|
|
-
|
-
|
-
|
|
|
|
|
3,141,823
|
3,441,142
|
7,491,633
|
|
Current assets
|
|
|
|
|
|
|
Cash and cash equivalents
|
|
|
48,017
|
84,431
|
11,519
|
|
Assets under construction
|
|
|
-
|
-
|
47,080
|
|
Trade and other
receivables
|
|
|
69,724
|
77,380
|
221,783
|
|
|
|
|
117,741
|
161,811
|
280,382
|
|
|
|
|
|
|
|
|
Current liabilities
|
|
|
|
|
|
|
Trade and other payables
|
|
|
3,388,129
|
2,565,666
|
2,136,161
|
|
Convertible loan notes
|
|
|
685,005
|
636,507
|
-
|
|
|
|
|
4,073,134
|
3,202,173
|
2,136,161
|
|
Non-Current liabilities
|
|
|
|
|
|
|
Convertible loan notes
|
|
|
-
|
-
|
-
|
|
|
|
|
|
|
|
|
Deferred tax liability
|
|
|
46,739
|
49,436
|
793,000
|
|
|
|
|
|
|
|
|
Total assets less liabilities
|
|
|
(860,309)
|
351,344
|
4,842,854
|
|
|
|
|
|
|
|
|
Capital and reserves
|
|
|
|
|
|
|
Share capital
|
|
|
5,756,057
|
5,756,057
|
5,756,057
|
|
Share premium
|
|
|
5,328,996
|
5,328,996
|
5,328,996
|
|
Equity to be issued
|
|
|
|
-
|
100,000
|
|
Share option reserve
|
|
|
50,015
|
48,398
|
51,357
|
|
Retained earnings
|
|
|
(11,995,377)
|
(10,782,107)
|
(6,393,556)
|
|
|
|
|
|
|
|
|
Total equity and liabilities
|
|
|
(860,309)
|
351,344
|
4,842,854
|
|
|
|
|
|
|
|
The consolidated interim financial
statements were approved and authorised for issue by the Board and
were signed on its behalf by:
Melissa Sturgess
Chief Executive Officer
[ [[30
October 2024
The notes form part of these
consolidated interim financial statements.
Consolidated Interim Statement of Changes in
Equity
|
GROUP
|
Share
Capital
|
Share
Premium
|
Share Option
Reserve
|
Retained
Earnings
|
Total
|
|
|
£
|
£
|
£
|
£
|
£
|
|
As
at 1 February 2024
|
5,756,057
|
5,328,996
|
48,398
|
(10,782,107)
|
351,344
|
|
|
|
|
|
|
|
|
Total comprehensive loss for the
period
|
-
|
-
|
-
|
(1,213,270)
|
(1,213,270)
|
|
|
|
|
|
|
|
|
Share based payment
|
-
|
-
|
1,617
|
-
|
1,617
|
|
|
|
|
|
|
|
|
Balance at 31 July 2024
|
5,756,057
|
5,328,996
|
50,015
|
(11,995,377)
|
(860,309)
|
|
GROUP
|
Share
Capital
|
Share
Premium
|
Share Option
Reserve
|
Retained
Earnings
|
Total
|
|
|
£
|
£
|
£
|
£
|
£
|
|
As
at 1 February 2023
|
2,341,110
|
3,468,944
|
32,499
|
(4,637,944)
|
1,204,609
|
|
|
|
|
|
|
|
|
Total comprehensive loss for the
year
|
-
|
-
|
-
|
(6,144,163)
|
(6,144,163)
|
|
|
|
|
|
|
|
|
Proceeds from share issue
|
3,414,947
|
1,860,052
|
-
|
-
|
5,274,999
|
|
Issue of share options
|
-
|
-
|
15,899
|
-
|
15,899
|
|
|
|
|
|
|
|
|
Balance at 31 January
2024
|
5,756,057
|
5,328,996
|
48,398
|
(10,782,107)
|
351,344
|
|
GROUP
|
Share
Capital
|
Share
Premium
|
Share Option
Reserve
|
Retained
Earnings
|
Total
|
|
|
£
|
£
|
£
|
£
|
£
|
|
As
at 1 February 2023
|
2,341,110
|
3,468,944
|
32,499
|
(5,403,663)
|
438,890
|
|
|
|
|
|
|
|
|
Total comprehensive loss for the
period
|
-
|
-
|
-
|
(989,893)
|
(989,893)
|
|
|
|
|
|
|
|
|
Proceeds from share issue
|
3,414,947
|
1,860,052
|
-
|
-
|
5,274,999
|
|
Issue of share options
|
-
|
-
|
18,858
|
-
|
18,858
|
|
Equity to be issued
|
-
|
-
|
100,000
|
-
|
100,000
|
|
|
|
|
|
|
|
|
Balance at 31 July 2023
|
5,756,057
|
5,328,996
|
151,357
|
(6,393,556)
|
4,842,854
|
The following describes the nature
and purpose of each reserve within owners' equity:
|
Reserve
|
Description and purpose
|
|
Share capital
|
This represents the nominal value of
shares issued.
|
|
Share premium
|
Amount subscribed for share capital
in excess of nominal value.
|
|
Retained earnings
|
Cumulative net gains and losses
recognised in the statement of comprehensive income.
|
The
notes form part of these consolidated interim financial
statements.
ACCOUNTING POLICIES
General information
Ananda Developments Plc's
consolidated interim financial statements are presented in British
Pound Sterling (GBP) which is the functional currency of the parent
company. These consolidated interim financial statements were
approved for issue by the Board of Directors on 30 October
2024.
The financial information set out in
these interim financial statements does not constitute statutory
accounts as defined in Section 434 of the Companies Act 2006. The
Company's statutory financial statements for the year ended 31
January 2024 have been filed with the Registrar of Companies. The
auditor's report on those financial statements was unqualified and
did not contain a statement under Section 498(2) of the Companies
Act 2006.
These interim results have not been
audited nor have they been reviewed by the Company's auditors under
ISRE 2410 of the Auditing Practices Board.
Basis of preparation
These consolidated interim financial
statements are for the six-month period ended 31 July 2024. They
have been prepared following the recognition and measurement
principles of FRS 102. They do not include all the information
required for full annual financial statements and should be read in
conjunction with the audited consolidated financial statements for
the period ended 31 January 2024.
These unaudited consolidated interim
financial statements have been prepared on a going concern basis
which the Directors believe to be appropriate.
These unaudited consolidated interim
financial statements have been prepared in accordance with the
accounting policies adopted in the consolidated financial
statements for the period ended 31 January 2024.
The principal accounting policies
applied in the preparation of these Interim financial statements
are the same as those applied in preparation of the group's annual
financial statements.
1.
Foreign currency
transactions
Transactions in foreign currencies
are translated to GBP at the exchange rates at the dates of the
transactions. Monetary assets and liabilities denominated in
foreign currencies at the reporting date are translated to GBP at
the exchange rate on that date. Foreign exchange differences
arising on translation are recognised in the statement of
comprehensive income.
2.
Earnings per share
The calculation of earnings per
share is based on the loss attributable to ordinary shareholders
divided by the average number of shares in issue during the
period.
SUBSEQUENT EVENTS
Raise via subscription and placing
Successfully
raised gross proceeds of £2,225,857 from new and existing
shareholders by way of a placing, subscription
(together the "Fundraise") and
WRAP
Retail Offer of new Ordinary
Shares at a price of 0.3 pence per share (the "Issue Price").
Highlights:
·
Ananda successfully raised gross proceeds of
£2,145,861 including a £2,040,800 subscription by Charles Morgan,
the Company's Chairman
·
In addition to the Fundraise, the Company offered
additional shares to existing shareholders through a retail
offering on the Winterflood Retail Access Platform
·
Charles Morgan and Melissa Sturgess (CEO) also
agreed to capitalise all unsecured debt owed to them, with
additional share authorities being granted at a general meeting on
8 October 2024. The capitalisation of this debt significantly
strengthened the Company's balance sheet
·
Proceeds of this Fundraise and WRAP Retail Offer
will be used to manufacture MRX1 for CIPN and Endometriosis Phase
II studies, execute a pharmacokinetic study for MRX1 in Australia
and general
working capital
·
The Company has also issued options to key
management personnel
Ananda cannabinoid medicines to be used in NHS epilepsy
trials
On 21 October
2024, Ananda announced that two of its patent pending cannabinoid
medicines, MRX2 and MRX2T, will be used in two NIHR- &
NHS-funded Phase IIIa epilepsy clinical trials involving up to 500
patients in total. The trials
will be run by investigators at University College London and Great
Ormond Street Hospital.
The objective of the trials is to
test the safety and efficacy of Ananda's specific cannabidiol (CBD)
and CBD plus THC formulations for two treatment-resistant epilepsy
groups in children and adults. If the results are favourable, they
will pave the way for a submission of these medicines to the MHRA
and other regulatory bodies for regulatory approval.
The trials are being funded by a
partnership between NHS England and National Institute for Health
and Care Research (NIHR) and will be co-led by Professor Finbar
O'Callaghan and Professor Helen Cross of University College London
(UCL) and Great Ormond Street Hospital for Children NHS Foundation
Trust (GOSH).
Highlights:
·
MRX formulations will be used as the
investigational medicinal products (IMPs) in two NIHR/NHS funded
Phase III randomised controlled trials (RCTs) investigating the
treatment of complex epilepsies
·
Trial 1: MRX2 (CBD), MRX2T (CBD + THC) versus
placebo in patients with refractory (drug-resistant) early onset
epilepsies.
·
Trial 2: MRX2 (CBD), MRX2T (CBD + THC)
versus placebo in patients of normal cognitive ability with
refractory genetic generalised epilepsies.
·
Existing evidence suggests cannabis-based
medicinal products are promising treatments for difficult to treat
epilepsies, with one CBD-only medicine already licenced to treat
three rare conditions associated with drug-resistant
epilepsy
·
Should the trials deliver successful results, MRX
intends to progress further regulatory and commercial development
activities of these medicines via a licensing option that has been
granted by UCL over any IP arising from these trials
In combination, the trials will
involve up to 500 patients from across the UK and together, will be
the largest investigational trials conducted to date for
cannabinoids as a treatment for refractory epilepsy
Graduation to APEX segment of the AQUIS Stock
Exchange
On 5th August, trading in the
Company's shares was moved to the senior Apex segment of the
Aquis Stock Exchange ("AQSE") Growth Market.
The Apex segment is reserved for
larger, more established businesses with a proven growth strategy
and which meet higher standards of corporate governance.
Phase 1 Pharmacokinetic Study of MRX1
On
9th October
2024, the Company announced that Ananda's Australian
subsidiary had signed a contract with Southern Star Research Pty
Ltd('SSR'), a leading Australian
Contract Research Organisation, to carry out a Phase 1 clinical
trial investigating the pharmacokinetic ("PK") profile,
tolerability and safety of the Company's lead investigative
asset,MRX1.
Highlights:
·
Contract signed for Phase 1PK study
·
The clinical trial will investigate the PK
profile, tolerability and safety of MRX1 in
healthy
volunteers
·
The data generated will inform future clinical
trials in patients and form an integral part of
any future regulatory applications, including with the MHRA in the
United Kingdom or FDA
in the United States
·
Collected data will form part of Ananda's MRX1
patent estate and wider intellectual property
portfolio
·
Significant financial advantages of running the
study in Australia, including an R&D Tax
Incentive of up to 43.5% of eligible research and development
costs
Addition to Scientific Advisory Board
Lastly, Professor
Marie Fallon has agreed to join the Company's Scientific Advisory
Board ("SAB") to provide the
Company with expert technical advice and guidance. The SAB is
Chaired by Professor Clive Page, a non-executive director of Ananda
Developments plc and it held its first meeting in Edinburgh in May
2024.
Prof. Fallon is also the lead
investigator for Ananda's Phase II study investigating the
pain-relieving effects of MRX1 in patients
with Chemotherapy Induced Peripheral Neuropathy.
Professor Marie Fallon
Marie Fallon (MD FRCP(Glas) FRCP(E)
MRCGP DCH DRCOG). Marie is a Professor of Palliative Medicine at
the
University of Edinburgh and is an
Honorary Consultant in Palliative Medicine based at the Edinburgh
Cancer
Centre. Marie has played a
significant role in research, leading both national and
international research studies around pain and cachexia in cancer
patients. Marie has led the development of international palliative
care guidelines such as ESMO for cancer pain and ASCO for
cachexia.
Marie has been Joint Editor of four
editions of the Oxford Textbook of Palliative Medicine which is the
reference textbook in the specialty. Prof. Fallon has edited
several other books and sits on numerous grant committees, as well
as being an editorial board member of the BMJ Supportive and
Palliative Care journal. Finally, of note, much of
Marie's recent and current research relates to
Low- and Middle-Income Countries (LMICs), where she is seeking
to address the issue of poor opioid
availability in LMICs.
-Ends-
To stay abreast of the latest
developments at Ananda, we encourage you to follow our social media
channels which are:
·
Investor Hub:
investors.anandadevelopments.com
·
Instagram:
https://instagram.com/anandadevelopments?igshid=YmMyMTA2M2Y=
·
LinkedIn: https://www.linkedin.com/company/anadevelopments/
·
Twitter:
https://twitter.com/AnandaPlc
·
Investor Meet Company:
https://www.investormeetcompany.com/ananda-developments-plc/register-investor
-Ends-
The Directors of the Company accept
responsibility for the contents of this announcement.
|
ANANDA DEVELOPMENTS PLC
|
+44
(0)7463 686 497
|
|
|
ir@anandadevelopments.com
|
|
Chief Executive Officer
|
|
|
Melissa Sturgess
|
|
|
|
|
|
Finance Director
|
|
|
Jeremy
Sturgess-Smith
|
|
|
|
|
|
SP
ANGEL CORPORATE FINANCE LLP
|
+44 (0)20
3470 0470
|
|
|
|
|
Corporate Finance
|
|
|
Richard Morrison
|
|
|
Caroline Rowe
|
|
|
|
|
|
Corporate Broking
|
|
|
Abigail Wayne
|
|
|
Rob Rees
|
|
|
Yellow Jersey PR (media enquiries)
Sarah MacLeod
Charles Goodwin
Zara McKinlay
|
+44 (0)20
3004 9512
ananda@yellowjerseypr.com
|
About Ananda Developments
Ananda is an AQSE-listed
life sciences company focused on the research and
clinical development of CBD-based therapies for a range of complex
inflammatory pain conditions.
For more information, please
visit: https://anandadevelopments.com
https://investors.anandadevelopments.com/link/7PlxkP